Despite concern expressed by the pharmaceutical industry that the UK would suffer as a result of Brexit, Catalyst Corporate Finance, the UK business of Alantra (adviser to the industry), argues that the UK’s decision to leave the European Union in fact represents a major opportunity for the country’s dynamic and world-leading pharmaceutical sector.
Brexit
This confidence was borne out by the announcement that two large pharmaceutical companies will invest more than £1 billion into UK research hubs, creating nearly 1,000 high-skilled jobs. This investment by German-based Qiagen and MSD, the company known as Merck in the US, comes as the government prepares to publish its industrial strategy to reassure UK business ahead of departure from the EU.